^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Genomic analysis to identify determinants of inherent response and resistance to elranatamab in MagnetisMM-3 cohort A.

Published date:
05/25/2023
Excerpt:
MagnetisMM-3 (NCT04649359) is an open-label, multicenter, non-randomized phase 2 study of elranatamab monotherapy in patients (pts) with multiple myeloma refractory to at least 1 proteasome inhibitor, 1 immunomodulatory drug and 1 anti-CD38 antibody....Genome wide copy number analysis showed that TNFRSF17 locus amplification was associated with non-response (p= 0.008).
DOI:
10.1200/JCO.2023.41.16_suppl.8045
Trial ID:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSEAND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A

Published date:
05/11/2023
Excerpt:
Genome wide copy number analysis showed that TNFRSF17 locus amplification was associated with non-response(p=0.008)….Features of high-risk disease were also associated with lack of response to elranatamab.
Trial ID: